Literature DB >> 14924175

Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis.

R L YEAGER, W G C MUNROE, F I DESSAU.   

Abstract

Entities:  

Keywords:  NICOTINIC ACID/derivatives; TUBERCULOSIS, PULMONARY/therapy

Mesh：

Substances：

Year:  1952        PMID： 14924175

Source DB:  PubMed          Journal:  Am Rev Tuberc        ISSN： 0096-0381


× No keyword cloud information.
  44 in total

1.  PYRAZINAMIDE COVERAGE AT THE TIME OF PULMONARY RESECTION FOR TUBERCULOSIS.

Authors:  J H FOSTER; D A KILLEN; W G RHEA; W L DIVELEY; R L MCCRACKEN; W W HUBBARD
Journal:  Ann Surg       Date:  1963-07       Impact factor: 12.969

2.  Hyperuricaemia due to pyrazinamide.

Authors:  J SCHNEEWEISS; G W POOLE
Journal:  Br Med J       Date:  1960-09-17

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

4.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

5.  Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.

Authors:  Zahoor Ahmad; Mostafa M Fraig; Gregory P Bisson; Eric L Nuermberger; Jacques H Grosset; Petros C Karakousis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

6.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

7.  Haemodialysis of pyrazinamide in uraemic patients.

Authors:  C Lacroix; A Hermelin; R Guiberteau; C Guyonnaud; J Nouveau; H Duwoos; O Lafont
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 8.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

9.  Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis.

Authors:  Pooja Gopal; Michelle Yee; Jickky Sarathy; Jian Liang Low; Jansy P Sarathy; Firat Kaya; Véronique Dartois; Martin Gengenbacher; Thomas Dick
Journal:  ACS Infect Dis       Date:  2016-08-08       Impact factor: 5.084

10.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.